There is no clinically validated dosing table for CJC-1295 or Ipamorelin. However, the general technique of subcutaneous injection—needle size, injection sites, and administration method—is standard medical knowledge widely applied to peptide injections. This general information can be reliably explained here, separate from any specific dosing recommendation for these particular unapproved compounds.
CJC-1295 and Ipamorelin Dosage Chart
A specific dosing table—in micrograms, milliliters, or injection units—cannot be responsibly provided. No regulatory body has approved a dosing protocol for CJC-1295 or ipamorelin, and the amounts used in published studies were administered under direct clinical supervision for specific research purposes, not as a template for current self-administration.
What is documented is the range used in controlled trials. The main human study on CJC-1295 tested single subcutaneous doses, with researchers identifying 30 and 60 micrograms per kilogram of body weight as eliciting sustained, dose-dependent hormonal responses with good tolerability. This study also tested multiple dosing regimens spread weekly or bi-weekly [1].
For ipamorelin, pharmacokinetic studies in humans have utilized intravenous infusions across a range of doses, with concentrations required for half-maximal growth hormone stimulation calculated at 214 nanomolar [2]. A separate clinical study in surgical patients employed a fixed intravenous dose of 0.03 milligrams per kilogram administered twice daily [3].
These numbers describe what was studied clinically, under monitored conditions, for specific research questions. They do not constitute a table intended for translation into a personal, repeatable schedule of self-injection, and no source in the reviewed literature validates a consumer dosing table for any of these compounds, whether used alone or in combination.
How to inject CJC-1295 and Ipamorelin
In general pharmacological terms, subcutaneous injection—a method used in the main human study of CJC-1295 [1]—involves placing a substance into the layer of fatty tissue just beneath the skin, rather than into a muscle or vein. This is the same general category of injection used for many other self-administered peptide and protein drugs, such as insulin.
Common sites for subcutaneous injection used in this broader category of medications include the abdomen (avoiding a five-centimeter radius around the navel), the front or outer thigh, and the back of the upper arm. Rotation of sites is generally recommended in standard medical practice to reduce irritation or tissue changes at one specific site.
This is general knowledge regarding injections, applicable to subcutaneous peptides as a category, rather than a set of instructions specific to CJC-1295 or ipamorelin derived from a dedicated study protocol. Published research on these compounds does not detail site selection guidance aimed at consumers.
What size needle for CJC-1295 and ipamorelin?
The clinical trials reviewed for this article do not specify the needle size or length used for administration, as needle selection in a research setting is a practical, clinical detail rather than a scientific finding published in the resulting scientific paper.
As general context, subcutaneous injections of peptide compounds are typically administered with short, thin needles – commonly in the 29–31 gauge range and approximately 4–8 millimeters in length. The aim is to reach the subcutaneous fat layer without penetrating deeper into the muscle. This is standard practice for many subcutaneously administered medications and not a number specific to CJC-1295 or ipamorelin studies.
Since there is no dedicated needle size study for these compounds, this number should be understood as a general subcutaneous injection convention rather than a validated recommendation for these specific peptides.
CJC-1295 injection frequency
The injection frequency in published studies varies significantly between these two compounds, stemming from their very different durations of action.
CJC-1295, in its long-acting form with DAC, has been tested with multiple dosing regimens administered solely weekly or bi-weekly. This is consistent with its long estimated half-life of approximately 5.8–8.1 days, which meant that less frequent dosing was sufficient in research settings to maintain elevated hormone levels [1].
Ipamorelin, on the other hand, has a significantly shorter half-life of about two hours and induces a single, sharp pulse of growth hormone release, peaking around 40 minutes after administration [2], [4]. This is why the clinical trial testing it for postoperative recovery used a twice-daily dosing schedule for the duration of treatment, rather than a weekly schedule [3].
This difference in frequency reflects the distinct pharmacokinetics of each compound, as studied in their respective clinical trials. However, this is not a validated schedule for the combination of both compounds administered together, as no published human studies have tested CJC-1295 and Ipamorelin administered on a shared injection schedule.
Limitations of current evidence
The numbers described above regarding frequency and dosage come from controlled clinical trials using specific routes of administration—subcutaneous for CJC-1295, intravenous for the cited ipamorelin studies—under medical supervision. They do not constitute a validated, general injection or dosing protocol for use.
Needle size and injection site recommendations reflect general subcutaneous injection conventions widely used in medicine, rather than discoveries specific to these two compounds. And no published study establishes a cumulative dosing schedule for CJC-1295 and ipamorelin together.
Disclaimer
This content is for educational purposes only and does not constitute medical advice, dosing guidance, or instructions for self-administration. CJC-1295 and Ipamorelin are research compounds and are not approved by the FDA or the European Medicines Agency for any medical use, whether used individually or in combination. The dosing, frequency, and injection information presented here reflects amounts and methods used in controlled clinical research settings under medical supervision and is not intended to direct or encourage self-administration. There is no validated consumer dosing chart or injection schedule for either of these compounds.
References
Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412–1416. https://doi.org/10.1023/a:1018955126402
Beck, D. E., Sweeney, W. B., McCarter, M. D., & Ipamorelin 201 Study Group. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527–1534. https://doi.org/10.1007/s00384-014-2030-8
[4] Johansen, P. B., Hansen, K. T., Andersen, J. V., & Johansen, N. L. (1998). Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica, 28(11), 1083–1092. https://doi.org/10.1080/004982598238976